{"id":"cni-50","safety":{"commonSideEffects":[{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Neurotoxicity (tremor, headache)"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Gingival hyperplasia"},{"rate":null,"effect":"Infections"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Calcineurin inhibitors bind to immunophilins (cyclophilin or FK-binding protein) and block calcineurin-mediated dephosphorylation of NFAT, a transcription factor essential for IL-2 and other cytokine gene expression in T cells. This prevents T-cell proliferation and differentiation, making them potent immunosuppressants used in transplantation and autoimmune diseases.","oneSentence":"CNI (calcineurin inhibitor) suppresses T-cell activation by inhibiting calcineurin phosphatase, thereby reducing production of pro-inflammatory cytokines.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:29:20.935Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Organ transplant rejection prophylaxis"},{"name":"Autoimmune and inflammatory conditions (e.g., atopic dermatitis, psoriasis)"}]},"trialDetails":[{"nctId":"NCT03663335","phase":"PHASE2","title":"Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-11-28","conditions":"Kidney Transplantation","enrollment":418},{"nctId":"NCT06291103","phase":"PHASE2, PHASE3","title":"Screening for Subclinical Antibody Mediated Rejection and Efficacy of Belatacept in the Context of de Novo Donor Specific Antibody After Kidney Transplantation (BELA-M-R)","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2026-03-01","conditions":"Kidney Transplant Rejection","enrollment":290},{"nctId":"NCT07355816","phase":"NA","title":"Effect of Different Root Canal Disinfection Procedures on Postoperative Pain","status":"COMPLETED","sponsor":"Cumhuriyet University","startDate":"2023-06-13","conditions":"Pain, Postoperative","enrollment":80},{"nctId":"NCT06829719","phase":"NA","title":"TTV-based mAnagement Of Long-term ImmunosuppreSsion in Kidney Transplantation","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2025-04-23","conditions":"Infection, Cancer, Rejection","enrollment":300},{"nctId":"NCT02711826","phase":"PHASE1, PHASE2","title":"Treg Therapy in Subclinical Inflammation in Kidney Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-09-20","conditions":"Kidney Transplant, Adult Living Donor Kidney Transplant Recipients, Renal Transplant","enrollment":32},{"nctId":"NCT02533180","phase":"PHASE2","title":"Evaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Tolerance Post Liver Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-12-15","conditions":"Liver Transplant, Liver Transplantation","enrollment":100},{"nctId":"NCT02883400","phase":"PHASE4","title":"Spironolactone After Liver Transplant","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2014-12","conditions":"Transplant, Liver","enrollment":30},{"nctId":"NCT01820572","phase":"PHASE3","title":"A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-03-27","conditions":"Kidney Transplantation","enrollment":446},{"nctId":"NCT02083991","phase":"PHASE4","title":"Trial of Steroid Avoidance and Low-dose CNI by ATG-induction in Renal Transplantation","status":"COMPLETED","sponsor":"Vastra Gotaland Region","startDate":"2013-01","conditions":"Diabetes Mellitus","enrollment":224},{"nctId":"NCT00377962","phase":"PHASE4","title":"Nordic Everolimus (Certican) Trial in Heart and Lung Transplantation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-12","conditions":"Disorder Related to Cardiac Transplantation","enrollment":282},{"nctId":"NCT00862979","phase":"PHASE4","title":"A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-02-24","conditions":"Heart Transplantation","enrollment":162},{"nctId":"NCT00716573","phase":"PHASE4","title":"Efficacy Study of Everolimus on Renal Function in Heart Transplant Recipients With Established Chronic Renal Failure","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2008-09-16","conditions":"Cardiac Transplantation, Chronic Renal Insufficiency","enrollment":120},{"nctId":"NCT00514514","phase":"PHASE3","title":"Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose Regimen","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-07","conditions":"Kidney Transplantation","enrollment":802},{"nctId":"NCT02058875","phase":"PHASE4","title":"Cardiovascular Risk Following Conversion to Full Dose Myfortic® and Neoral® Two-hour Post Level Monitoring","status":"WITHDRAWN","sponsor":"University of Saskatchewan","startDate":"2014-02","conditions":"Cardiovascular Disease, Cardiovascular Outcomes, Kidney Transplant Recipients","enrollment":""},{"nctId":"NCT01169701","phase":"PHASE4","title":"24 Months Follow-up, Two Arm Study to Compare the Cardiovascular Profile in a Regimen With Everolimus + Mycophenolic Acid (MPA) Versus (vs.) a Regimen of CNI+MPA in Maintenance Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-08","conditions":"Renal Transplant","enrollment":71},{"nctId":"NCT01781195","phase":"","title":"Delayed CNI-based Immunosuppression With Advagraf After MELD-based Liver Transplantation","status":"UNKNOWN","sponsor":"Heidelberg University","startDate":"2013-02","conditions":"Liver Graft Dysfunction","enrollment":50},{"nctId":"NCT01678937","phase":"","title":"Immune Tolerance and Alloreactivity in Liver Transplant Recipients on Different Monotherapy Immunosuppressive Agents","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2007-09","conditions":"Liver Transplant Rejection, Immunosuppression","enrollment":31},{"nctId":"NCT00717314","phase":"PHASE4","title":"A Study of CellCept (Mycophenolate Mofetil) Combined With Calcineurin Inhibitors in Liver Transplant Patients.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-05","conditions":"Liver Transplantation","enrollment":87},{"nctId":"NCT00634920","phase":"PHASE4","title":"Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-03","conditions":"Renal Function","enrollment":204},{"nctId":"NCT01596062","phase":"PHASE2","title":"Pharmacodynamics, Efficacy and Safety of Basiliximab 40 or 80 mg in Combination With Ciclosporine Microemulsion or Everolimus, in Adult Low Risk de Novo Renal Transplant Recipients (IDEALE Study)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-03","conditions":"Renal Transplantation","enrollment":16},{"nctId":"NCT01079143","phase":"PHASE3","title":"Progression of Renal Interstitial Fibrosis / Tubular Atrophy (IF/TA) According to Epithelial-mesenchymal Transition (EMT) and Immunosuppressive Regimen (Everolimus Based Versus CNI Based) in de Novo Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-09","conditions":"Renal Interstitial Fibrosis","enrollment":194},{"nctId":"NCT01609673","phase":"NA","title":"Study of Everolimus in de Novo Renal Transplant Recipients","status":"TERMINATED","sponsor":"Helady Pinheiro, MD, PhD","startDate":"2013-03","conditions":"End Stage Renal Failure With Renal Transplant","enrollment":1},{"nctId":"NCT00777400","phase":"PHASE1, PHASE2","title":"Pilot Trial to Assess Effect of CNI Conversion of Efalizumab on T Reg Cells","status":"WITHDRAWN","sponsor":"University of California, San Francisco","startDate":"2008-12","conditions":"Autoimmune Diseases","enrollment":""},{"nctId":"NCT01321112","phase":"NA","title":"Search for Transcriptional Biomarkers in a Conversion Protocol From Calcineurin Inhibitors to Mycophenolate Mofetil","status":"UNKNOWN","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2011-02","conditions":"Gene Expression, Immunosuppression Conversion, Liver Transplantation","enrollment":40},{"nctId":"NCT01213394","phase":"PHASE3","title":"Mycophenolate Mofetil for Reducing Cardiovascular Risk in Renal Transplant Recipients","status":"TERMINATED","sponsor":"Ramesh Prasad","startDate":"2010-10","conditions":"Kidney Transplantation, Cardiovascular Diseases","enrollment":2},{"nctId":"NCT00596557","phase":"PHASE4","title":"Everolimus and Low Dose CNI Compared With MMF and Full CNI Dose in Heart Transplanted Patients: One Year Follow up","status":"COMPLETED","sponsor":"Rabin Medical Center","startDate":"2008-02","conditions":"Chronic Rejection of Cardiac Transplant","enrollment":20},{"nctId":"NCT00903188","phase":"PHASE4","title":"Calcineurin Inhibitor (CNI) Versus Steroid Cessation in Renal Transplantation","status":"UNKNOWN","sponsor":"University Hospital, Antwerp","startDate":"2008-10","conditions":"Renal Transplantation","enrollment":152},{"nctId":"NCT00684372","phase":"NA","title":"BK Viremia After Renal Transplantation","status":"UNKNOWN","sponsor":"Karolinska University Hospital","startDate":"2007-05","conditions":"Terminal Renal Failure, BK Virus Infection","enrollment":100},{"nctId":"NCT00541814","phase":"PHASE4","title":"Calcineurin Inhibitor Minimisation in Renal Transplant Recipients With Stable Allograft Function","status":"UNKNOWN","sponsor":"University Hospital Birmingham","startDate":"2007-10","conditions":"Chronic Allograft Nephropathy","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":349,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"CNI (50%)","genericName":"CNI (50%)","companyName":"Hoffmann-La Roche","companyId":"roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CNI (calcineurin inhibitor) suppresses T-cell activation by inhibiting calcineurin phosphatase, thereby reducing production of pro-inflammatory cytokines. Used for Organ transplant rejection prophylaxis, Autoimmune and inflammatory conditions (e.g., atopic dermatitis, psoriasis).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}